characterizing cardiovascular outcomes associated with … · 2020. 7. 22. · 1)leukapheresis: t...

Characterizing Cardiovascular Outcomes Associated withChimeric Antigen Receptor T Cell Therapy

Background

Results & DiscussionResearch Question:Among cancer patients treated with CAR-T cell therapy, what adverse cardiovascular outcomes occur, and are what are the identifiable risk factors exist?

Michael Rothberg, Patrick Holman MD, Daria Gaut MD, Joshua Sasine MD PhD,Tomas Neilan MD MPH, Syed Saad Mahmood MD, Eric Yang MD

References

Conclusions

• We included 60 patients receiving standard of care CAR T at UCLAsince 2017 Patients receiving CAR-T as part of a clinical trial wereexcluded from the study.

• Patients were stratified into CV Event or Control (no cardiovascularevent developed) groups.

• “CV Event” (Major Adverse Cardiovascular Event or MACE)defined as

1) CV death from HF, cardiogenic shock, cardiac arrest orarrhythmia

2) New evidence of heart failure (HF)3) Clinically significant de novo arrhythmias (e.g. SVT, Afib,

excluding QTc prolongation)

4) Non-Fatal Acute Coronary Syndrome (with evidence ofLVEF decrease >10% to final LVEF of